BioNTech SE Sponsored ADR $BNTX Holdings Boosted by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. raised its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 80.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,746 shares of the company’s stock after purchasing an additional 779 shares during the quarter. PNC Financial Services Group Inc.’s holdings in BioNTech were worth $186,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. SBI Securities Co. Ltd. grew its holdings in shares of BioNTech by 5.2% during the second quarter. SBI Securities Co. Ltd. now owns 3,865 shares of the company’s stock valued at $412,000 after buying an additional 192 shares in the last quarter. Allworth Financial LP lifted its position in BioNTech by 1,176.8% in the 2nd quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock worth $129,000 after buying an additional 1,118 shares in the last quarter. Profund Advisors LLC boosted its stake in shares of BioNTech by 3.6% during the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after buying an additional 149 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of BioNTech during the 2nd quarter valued at $303,000. Finally, Bank of New York Mellon Corp increased its stake in shares of BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after acquiring an additional 410,351 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on BNTX. JPMorgan Chase & Co. reduced their price objective on BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research report on Thursday, October 23rd. Cowen reiterated a “hold” rating on shares of BioNTech in a report on Monday, November 3rd. Morgan Stanley restated an “overweight” rating and issued a $134.00 price objective on shares of BioNTech in a report on Monday, November 3rd. UBS Group lifted their target price on shares of BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.20.

BioNTech Trading Up 3.0%

NASDAQ:BNTX opened at $102.70 on Friday. The company’s 50 day moving average is $102.96 and its 200-day moving average is $105.00. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $129.27. The firm has a market cap of $23.13 billion, a price-to-earnings ratio of -64.19 and a beta of 1.54.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.BioNTech’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.81 earnings per share. BioNTech has set its FY 2025 guidance at EPS. Equities analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.